Retatrutide Dosing and Titration in a Research Setting: What the TRIUMPH Data Tells Clinic Owners

The TRIUMPH trial program — the Phase 3 clinical trial series evaluating retatrutide for obesity and type 2 diabetes — established a clear dosing and titration framework that is the most reliable reference point for clinic owners developing a practice-based research protocol. Understanding what the trial data shows, and what it does not show, is essential for designing a protocol that is both clinically sound and defensible.

The TRIUMPH trials evaluated retatrutide at multiple dose levels, with a structured titration schedule designed to minimize GI side effects while achieving therapeutic exposure. The general framework from the published Phase 2 data (which informed the Phase 3 design) involved:

Starting dose: 2 mg subcutaneous injection once weekly

Titration schedule: Dose escalation at 4-week intervals, contingent on tolerability:

• 2 mg once weekly (weeks 1–4)
• 4 mg once weekly (weeks 5–8)
• 8 mg once weekly (weeks 9–12)
• 12 mg once weekly (maintenance, for patients in the higher-dose cohort)

The Phase 2 data showed dose-dependent weight loss, with the highest dose cohort (12 mg) achieving mean weight loss of approximately 24% at 48 weeks — substantially greater than what has been observed with semaglutide or tirzepatide at their approved doses.

The titration schedule is not arbitrary. GLP/GIP/glucagon triple agonists produce significant GI side effects — nausea, vomiting, diarrhea — particularly during dose escalation. The structured titration schedule allows the GI tract to adapt to the compound gradually, reducing the severity and duration of these side effects.

Skipping titration steps or escalating too quickly increases the risk of severe GI side effects, which can lead to dehydration, electrolyte imbalances, and patient discontinuation. For a practice-based research protocol, maintaining the titration schedule is both a clinical best practice and a protocol compliance requirement.

The TRIUMPH trial used a fixed titration schedule, but clinical practice often requires flexibility. Your IRB protocol should specify how dose modifications will be handled — specifically:

• Dose delay: If a patient experiences significant GI side effects, the protocol should specify the criteria for delaying dose escalation (e.g., remaining at the current dose for an additional 4 weeks before attempting escalation)
• Dose reduction: If a patient cannot tolerate a given dose level, the protocol should specify the criteria for reducing the dose and the process for attempting re-escalation
• Discontinuation criteria: The protocol should specify the criteria for discontinuing the compound entirely — both for safety reasons and for patient preference

These modifications should be documented in the patient's research record and, if they represent a deviation from the protocol, reported to the IRB.

The TRIUMPH trials included structured monitoring visits during the titration period. For a practice-based protocol, reasonable monitoring might include:

• Baseline assessment: Weight, BMI, vital signs, relevant laboratory values (HbA1c, lipid panel, renal function, thyroid function), and documentation of comorbidities
• Monthly visits during titration: Weight, vital signs, assessment of GI side effects, and documentation of any adverse events
• Quarterly visits during maintenance: Weight, vital signs, laboratory monitoring (at minimum renal function and thyroid function), and adverse event documentation

The specific monitoring schedule should be specified in your protocol and reviewed by your IRB.

The TRIUMPH trial data is compelling, but it has limitations that clinic owners should understand:

• Long-term safety data is limited: The Phase 3 trials are ongoing. Long-term cardiovascular outcomes data, similar to the SUSTAIN and SURPASS trials for semaglutide and tirzepatide, is not yet available for retatrutide.
• The trial population is not your patient population: Clinical trial participants are selected and monitored more carefully than typical clinical patients. Real-world outcomes may differ.
• Drug interactions are not fully characterized: The interaction profile of retatrutide with commonly prescribed medications has not been fully studied.

These limitations should be reflected in your informed consent document and discussed with patients during the consent process.

A practice-based research protocol for retatrutide should have a qualified medical director who is responsible for clinical oversight of the study. This person should be familiar with the TRIUMPH trial data, experienced in obesity medicine, and available to manage adverse events and protocol deviations as they arise.

The medical director is not just a signature on the protocol. They are the clinical backstop for the research — the person who makes the judgment calls when the protocol does not cover a specific situation.